Pfizer Issues Multiple Note Series
Ticker: PFE · Form: 8-K · Filed: 2025-11-21T00:00:00.000Z
Sentiment: neutral
Topics: debt-issuance, financing, notes
Related Tickers: PFE
TL;DR
Pfizer just dropped new debt: notes due 2027, 2029, 2032, 2037, and 2045.
AI Summary
On November 18, 2025, Pfizer Inc. filed an 8-K report detailing the issuance of several series of notes. These include $1.000 Notes due 2027, $2.875 Notes due 2029, $3.250 Notes due 2032, $3.875 Notes due 2037, and $4.250 Notes due 2045. The filing indicates these notes were issued under the company's existing debt structure.
Why It Matters
This filing indicates Pfizer is actively managing its debt by issuing new notes, which could impact its capital structure and future financing costs.
Risk Assessment
Risk Level: low — The filing is a routine debt issuance announcement and does not contain any negative or unexpected information.
Key Numbers
- 2027 — Maturity Year (Maturity year for one series of notes)
- 2029 — Maturity Year (Maturity year for one series of notes)
- 2032 — Maturity Year (Maturity year for one series of notes)
- 2037 — Maturity Year (Maturity year for one series of notes)
- 2045 — Maturity Year (Maturity year for one series of notes)
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- November 18, 2025 (date) — Date of earliest event reported
- $1.000 Notes due 2027 (dollar_amount) — Debt instrument issued
- $2.875 Notes due 2029 (dollar_amount) — Debt instrument issued
- $3.250 Notes due 2032 (dollar_amount) — Debt instrument issued
- $3.875 Notes due 2037 (dollar_amount) — Debt instrument issued
- $4.250 Notes due 2045 (dollar_amount) — Debt instrument issued
FAQ
What is the aggregate principal amount of each series of notes issued by Pfizer?
The filing does not specify the aggregate principal amount for each series of notes, only the coupon rates and maturity dates.
What is the purpose of issuing these new notes?
The filing does not explicitly state the purpose, but it is a routine debt issuance, likely for general corporate purposes or refinancing.
Are these notes senior or subordinated debt?
The filing does not specify the seniority of these notes.
What are the specific interest rates for each note series?
The filing lists the interest rates as 1.000%, 2.875%, 3.250%, 3.875%, and 4.250% for the respective note series.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 18, 2025.
From the Filing
0001193125-25-291406.txt : 20251121 0001193125-25-291406.hdr.sgml : 20251121 20251121161649 ACCESSION NUMBER: 0001193125-25-291406 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20251118 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251121 DATE AS OF CHANGE: 20251121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 251508195 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 d80089d8k.htm 8-K 8-K PFIZER INC false 0000078003 0000078003 2025-11-18 2025-11-18 0000078003 us-gaap:CommonStockMember 2025-11-18 2025-11-18 0000078003 pfe:M1.000NotesDue20275Member 2025-11-18 2025-11-18 0000078003 pfe:M2.875NotesDue20291Member 2025-11-18 2025-11-18 0000078003 pfe:M3.250NotesDue20322Member 2025-11-18 2025-11-18 0000078003 pfe:M3.875NotesDue20373Member 2025-11-18 2025-11-18 0000078003 pfe:M4.250NotesDue20454Member 2025-11-18 2025-11-18     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 18, 2025     PFIZER INC. (Exact name of registrant as specified in its charter)       Delaware   1-3619   13-5315170 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   66 Hudson Boulevard East   New York , New York   10001-2192 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (212) 733-2323 (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.05 par value   PFE   New York Stock Exchange 1.000% Notes due 2027   PFE/27   New York Stock Exchange 2.875% Notes due 2029   PFE/29   New York Stock Exchange 3.250% Notes due 2032   PFE/32   New York Stock Exchange 3.875% Notes due 2037   PFE/37A   New York Stock Exchange 4.250% Notes due 2045   PFE/45   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial acco